DMSI OTC

Dermisonics, Inc. develops and produces ultrasonic technologies and equipment for the transdermal administration of medications. A core focus for the company is the creation, evaluation, and market launch of its unique active transdermal patch, known as the U-Strip. This innovative patch is designed to facilitate the needle-free entry of large molecular weight drugs, like Insulin, directly into the circulatory system. The firm was originally incorporated as Second Stage Ventures, Inc. before adopting its current name, Dermisonics, Inc., in October 2004. Founded in 2000, the company maintains its principal offices in Irvine, California.